Autism Speaks National Conference for Families and Professionals
1st Annual Autism Investment Conference
26 July 26 - July 27, 2013
The Hilton Columbus at Easton Columbus, Ohio

Confirmed Speakers

Jeremy Veenstra–VanderWeele, MD  photo

Jeremy Veenstra–VanderWeele, MD

Medical Director

Treatment and Research Institute for Autism Spectrum Disorder

Jeremy Veenstra-VanderWeele, M.D., is a child psychiatrist and molecular neuroscientist focused on understanding how autism risk factors lead to changes in brain and behavior, with the goal of translating a better understanding of neurobiology into new treatments. He trained in human molecular genetics in the laboratory of Edwin H. Cook at the University of Chicago. Concurrently, he received clinical training in psychiatry and child and adolescent psychiatry, with a special emphasis on autism spectrum disorders (ASD).  He then completed a post-doctoral research fellowship in molecular neuroscience, with the goal to work at the interface between mouse models related to autism and the translation of findings in animal models into novel treatments. His current work includes studies of the serotonin, oxytocin and glutamate systems in mice.  He has also developed a research program in translational treatments for Fragile X Syndrome and Autism Spectrum Disorder within the Vanderbilt Treatment and Research Institute for Autism Spectrum Disorders (TRIAD). Clinically, he leads the Vanderbilt Treatment Resistant Autism Consultation Clinic and serves as the psychiatry sub-specialist for the Vanderbilt Autism Speaks Autism Treatment Network (AS-ATN) site. Within the AS-ATN, he is the co-chair of the Psychopharmacology Working Group and also serves as the co-chair of the American Academy of Child and Adolescent Psychiatry Autism and Intellectual Disability Committee. As a content expert on Vanderbilt’s previous Agency for Healthcare Research and Quality evidence based review of treatments for children with ASD, he is acutely aware of the need for new treatments and for clearer evidence regarding the use of available treatments.



Powered by ConferenceNet from OnTrack Communications